- Geron Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
- Geron Announces FDA Approval of RYTELO™ (imetelstat), a First-in-Class Telomerase Inhibitor, for the Treatment of Adult Patients with Lower-Risk MDS with Transfusion-Dependent Anemia
- Geron Corporation Reports First Quarter 2024 Financial Results and Business Highlights
- Geron to Announce First Quarter 2024 Financial Results on May 2, 2024
Key statistics
On Wednesday, Geron Corp (GERN:NSQ) closed at 4.36, -18.35% below its 52-week high of 5.34, set on Jun 12, 2024.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 4.20 |
---|---|
High | 4.41 |
Low | 4.20 |
Bid | 4.36 |
Offer | 4.43 |
Previous close | 4.17 |
Average volume | 10.26m |
---|---|
Shares outstanding | 593.13m |
Free float | 592.61m |
P/E (TTM) | -- |
Market cap | 2.47bn USD |
EPS (TTM) | -0.3464 USD |
Data delayed at least 15 minutes, as of Jul 03 2024 18:00 BST.
More ▼